Medical Tube Dealers in Kandivali West, Mumbai

• Country of Origin: India
• Material: PVC
• Shape: Tube
• Color: Clear, Transparent
• Size: 5, 6, 7, 8, 9, 10
• Brand Name: Surgipal
• Product Code: SUR 1012

Product Feature: ·        Manufactured from transparent, non toxic, bio compatible PVC. ·        DEHP free. ·        Soft, smooth, kink resistant tubing for nutritional feeding and administration of medicine in neonates and infants. ·        Closed distal end with two lateral eyes. ·        With graduation marks for easy and precise placement. ·        Radio opaque line provided throughout the length of catheter for location verification by X-ray. ·        Catheter Length: 40, 50 cm.  

• Material: Non-toxic And Biocompatible PVC
• Size: Length Of The Tube 105 cm.
• Type: Sterile/ Non Sterile
• Packaging Type: Packet and Boxes
• Product Code: DP-GE-VSG-10050

• CATEGORY: Oncology Injectionables
• Dosage: 5mg
• Grade Standard: Medicine Grade
• Storage: Cool and Dry Place
• Form: Tablets / Liquid / Capsules / Powder
• Packaging Type: Plastic Bottle
• Storage: Cool and Dry Place
• Usage: Clinical, hospital etc.

Pamidronate Disodium  IV Infusion BP 30 mg & 60 mg is used in  treatment of moderate to severe hypercalcemia associated with malignancy with or without bone metastases; treatment of moderate to severe Paget disease of bone; treatment of osteolytic bone lesions of multiple myeloma and bone metastases of breast cancer in conjunction with standard chemotherapy. 3s corporation is Supplier,Exporter ,Wholesaler  for Pamidronate Disodium  IV Infusion BP 30 mg & 60 mg in India. India has many manufacturers who manufacture Pamidronate Disodium  IV Infusion BP 30 mg & 60 mg .To know more contact us.     ADDITIONAL INFORMATION Moderate to Severe Hypercalcemia of MalignancyAdults IV For moderate, give 60 to 90 mg as an initial single-dose infusion over 2 to 24 h. For severe, give 90 mg as an initial single-dose infusion over 2 to 24 h. For retreatment, same as initial therapy, at least 7 days after initial dose. Paget DiseaseAdults IV 30 mg/day as a 4-h infusion on 3 consecutive days for a total dose of 90 mg. For retreatment, same as initial therapy, when clinically indicated. Osteolytic Bone Metastases of Breast CancerAdults IV 90 mg as a 2-h infusion every 3 to 4 wk. Osteolytic Bone Lesions of Multiple MyelomaAdults IV 90 mg as a 4-h infusion on a monthly basis.   SIDE EFFECTS CARDIOVASCULAR Atrial fibrillation; atrial flutter; cardiac failure; hypertension; syncope; tachycardia. CNS Asthenia; anxiety; fatigue; headache; insomnia; paresthesia; psychosis; somnolence. DERMATOLOGIC Sweating. ENDOCRINE Hypothyroidism. GI Abdominal pain; anorexia; constipation; diarrhea; dyspepsia; GI hemorrhage; nausea; stomatitis; vomiting. GENITOURINARY UTI; uremia; renal toxicity. HEMATOLOGIC-LYMPHATIC Anemia; granulocytopenia; leukopenia; neutropenia; thrombocytopenia. LAB TESTS Hypocalcemia; hypokalemia; hypomagnesemia; hypophosphatemia. LOCAL Infusion-site reaction. MUSCULOSKELETAL Arthralgia; arthrosis; back pain; bone pain; musculoskeletal pain; myalgia; osteonecrosis primarily of the jaws. RESPIRATORY Coughing; dyspnea; pleural effusion; rales; rhinitis; sinusitis; upper respiratory infection. MISCELLANEOUS Edema; fever; metastases; moniliasis; pain; allergic manifestations (eg, hypotension, dyspnea, angioedema, anaphylactic shock) .